Saturn TMVR System
Mitral Regurgitation (MR)
Early Feasibility StudyActive
Key Facts
About InnovHeart
InnovHeart is a private, clinical-stage medical device company targeting the significant unmet need in mitral valve disease, specifically mitral regurgitation (MR). Its lead program, the Saturn TMVR system, has entered early feasibility studies in Europe, with first-in-human trans-septal implantation reported in 2024 and initial patient results published in 2025. The company is positioning itself in a multi-billion dollar market opportunity by developing a transcatheter solution tailored to the mitral valve's complex anatomy, leveraging the commercial success of transcatheter aortic valve replacement (TAVR) as a roadmap. Leadership combines founding technical expertise with seasoned industry executive experience.
View full company profile